WASHINGTON--(BUSINESS WIRE)--ClearFlow, Inc., a medical device company based in Anaheim, CA, today announced positive results from the Prevention of Retained Blood Outcomes Using Active Clearance Technology trial (PRO-ACT), a clinical study evaluating the use of PleuraFlow® Active Clearance Technology™ System to prevent retained blood complications. The PleuraFlow System enables caregivers to actively keep chest drainage tubes clear of clot in the early hours after heart surgery.
Help employers find you! Check out all the jobs and post your resume.